TAT-NEP1-40 as a novel therapeutic candidate for axonal regeneration and functional recovery after stroke

Journal of Drug Targeting

Volumn 19, Issue 2, 2011, Pages 86-95

  Gou, Xingchun ^a,b   Wang, Qiang ^b,c   Yang, Qianzi ^b   Xu, Lixian ^c   Xiong, Lize ^b  

^a XI'AN MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Axonal regeneration; NEP1 40; Nogo receptor; Protein transduction domain; Stroke; Transactivator of transcription

Indexed keywords

GLUCOSE; HYBRID PROTEIN; OXYGEN; PROTEIN NOGO A; PROTEIN NOGO A EXTRACELLULAR PEPTIDE RESIDUES 1-40; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BIOLOGICAL ACTIVITY; BLOOD BRAIN BARRIER; BRAIN DEGENERATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CELL STRAIN; CULTURE MEDIUM; HUMAN; IN VIVO STUDY; NERVE CELL LESION; NERVE FIBER GROWTH; NERVE FIBER REGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; REPERFUSION INJURY; SPINAL CORD INJURY; STROKE; TRAUMATIC BRAIN INJURY;

ANIMALS; AXONS; DRUG DELIVERY SYSTEMS; GENE PRODUCTS, TAT; GPI-LINKED PROTEINS; HUMANS; MYELIN PROTEINS; NERVE REGENERATION; PC12 CELLS; PEPTIDE FRAGMENTS; RATS; RECEPTORS, CELL SURFACE; RECOVERY OF FUNCTION; STROKE;

EID: 78650545994     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/10611861003733961     Document Type: Article

References (75)

1. Atalay B, Bavbek M, Cekinmez M, Ozen O, Nacar A, Karabay G, Gulsen S. (2007). Antibodies neutralizing Nogo-A increase pancadherin expression and motor recovery following spinal cord injury in rats. Spinal Cord, 45, 780-786. (Pubitemid 350224262)
2. Atalay B, Bavbek M, Ozen O, Nacar A, Gülsen S, Yigitkanli K, Caner H, Altinörs N. (2008). Nogo-A inhibitory peptide (NEP1-40) increases pan-cadherin expression following mild cortical contusion injury in rats. Turk Neurosurg, 18, 356-365.
3. Atwal JK, Pinkston-Gosse J, Syken J, Stawicki S, Wu Y, Shatz C, Tessier- Lavigne M. (2008). PirB is a functional receptor for myelin inhibitors of axonal regeneration. Science, 322, 967-970.
4. Barton WA, Liu BP, Tzvetkova D, Jeffrey PD, Fournier AE, Sah D, Cate R, Strittmatter SM, Nikolov DB. (2003). Structure and axon outgrowth inhibitor binding of the Nogo-66 receptor and related proteins. EMBO J, 22, 3291-3302. (Pubitemid 36834859)
5. Becker-Hapak M, McAllister SS, Dowdy SF. (2001). TAT-mediated protein transduction into mammalian cells. Methods, 24, 247-256. (Pubitemid 32846431)
6. Cao Y, Shumsky JS, Sabol MA, Kushner RA, Strittmatter S, Hamers FP, Lee DH, Rabacchi SA, Murray M. (2008). Nogo-66 receptor antagonist peptide (NEP1-40) administration promotes functional recovery and axonal growth after lateral funiculus injury in the adult rat. Neurorehabil Neural Repair, 22, 262-278. (Pubitemid 351561674)
7. Cao Z, Gao Y, Deng K, Williams G, Doherty P, Walsh FS. (2010). Receptors for myelin inhibitors: Structures and therapeutic opportunities. Mol Cell Neurosci, 43, 1-14.
8. Chivatakarn O, Kaneko S, He Z, Tessier-Lavigne M, Giger RJ. (2007). The Nogo-66 receptor NgR1 is required only for the acute growth cone-collapsing but not the chronic growth-inhibitory actions of myelin inhibitors. J Neurosci, 27, 7117-7124. (Pubitemid 47037553)
9. Denicourt C, Dowdy SF. (2003). Protein transduction technology offers novel therapeutic approach for brain ischemia. Trends Pharmacol Sci, 24, 216-218. (Pubitemid 36588866)
10. Domeniconi M, Cao Z, Spencer T, Sivasankaran R, Wang K, Nikulina E, Kimura N, Cai H, Deng K, Gao Y, He Z, Filbin M. (2002). Myelinassociated glycoprotein interacts with the Nogo66 receptor to inhibit neurite outgrowth. Neuron, 35, 283-290. (Pubitemid 34876731)
11. Donnan GA, Fisher M, Macleod M, Davis SM. (2008). Stroke. Lancet, 371, 1612-1623. (Pubitemid 351626845)
12. Dupuis L, Pehar M, Cassina P, Rene F, Castellanos R, Rouaux C, Gandelman M, Dimou L, Schwab ME, Loeffler JP, Barbeito L, Gonzalez de Aguilar JL. (2008). Nogo receptor antagonizes p75NTR-dependent motor neuron death. Proc Natl Acad Sci USA, 105, 740-745. (Pubitemid 351171778)
13. Edaravone Acute Infarction Study Group. (2003). Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis, 15, 222-229.
14. Egleton RD, Davis TP. (1997). Bioavailability and transport of peptides and peptide drugs into the brain. Peptides, 18, 1431-1439. (Pubitemid 27519756)
15. Fawell S, Seery J, Daikh Y, Moore C, Chen LL, Pepinsky B, Barsoum J. (1994). Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA, 91, 664-668. (Pubitemid 24041462)
16. Feigin VL. (2005). Stroke epidemiology in the developing world. Lancet, 365, 2160-2161.
17. Filbin MT. (2003). Myelin-associated inhibitors of axonal regeneration in the adult mammalian CNS. Nat Rev Neurosci, 4, 703-713. (Pubitemid 37280150)
18. Filbin MT. (2008). PirB, a second receptor for the myelin inhibitors of axonal regeneration Nogo66, MAG, and OMgp: Implications for regeneration in vivo. Neuron, 60, 740-742.
19. Fisher M, Bastan B. (2008). Treating acute ischemic stroke. Curr Opin Drug Discov Devel, 11, 626-632.
20. Fournier AE, Gould GC, Liu BP, Strittmatter SM. (2002). Truncated soluble Nogo receptor binds Nogo-66 and blocks inhibition of axon growth by myelin. J Neurosci, 22, 8876-8883.
21. Fournier AE, GrandPre T, Strittmatter SM. (2001). Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration. Nature, 409, 341-346. (Pubitemid 32151238)
22. Frankel AD, Pabo CO. (1988). Cellular uptake of the tat protein from human immunodeficiency virus. Cell, 55, 1189-1193.
23. Galvin R, Murphy B, Cusack T, Stokes E. (2008). The impact of increased duration of exercise therapy on functional recovery following stroke-what is the evidence? Top Stroke Rehabil, 15, 365-377.
24. GrandPré T, Li S, Strittmatter SM. (2002). Nogo-66 receptor antagonist peptide promotes axonal regeneration. Nature, 417, 547-551. (Pubitemid 34595921)
25. Green M, Loewenstein PM. (1988). Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell, 55, 1179-1188. (Pubitemid 19020070)
26. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995). Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med, 333, 1581-1587.
27. Guégan C, Braudeau J, Couriaud C, Dietz GP, Lacombe P, Bähr M, Nosten-Bertrand M, Onténiente B. (2006). PTD-XIAP protects against cerebral ischemia by anti-apoptotic and transcriptional regulatory mechanisms. Neurobiol Dis, 22, 177-186.
28. Guo F, Li SQ, Chu YH, Huang XF, Sun LM, Li YQ, Li HJ, Zhou TH. (2007). High-level expression, polyclonal antibody preparation and sub-cellular localization analysis of mouse Rhox5 protein. Protein Expr Purif, 54, 247-252. (Pubitemid 46783602)
29. Harvey PA, Lee DH, Qian F, Weinreb PH, Frank E. (2009). Blockade of Nogo receptor ligands promotes functional regeneration of sensory axons after dorsal root crush. J Neurosci, 29, 6285-6295.
30. Hou S, Tian W, Xu Q, Cui F, Zhang J, Lu Q, Zhao C. (2006). The enhancement of cell adherence and inducement of neurite outgrowth of dorsal root ganglia co-cultured with hyaluronic acid hydrogels modified with Nogo-66 receptor antagonist in vitro. Neuroscience, 137, 519-529. (Pubitemid 43031517)
31. Kastin AJ, Pan W. (2005). Targeting neurite growth inhibitors to induce CNS regeneration. Curr Pharm Des, 11, 1247-1253. (Pubitemid 40458270)
32. Kilic E, Kilic U, Hermann DM. (2006). TAT fusion proteins against ischemic stroke: Current status and future perspectives. Front Biosci, 11, 1716-1721. (Pubitemid 43253389)
33. Kilic U, Kilic E, Dietz GP, Bähr M. (2003). Intravenous TAT-GDNF is protective after focal cerebral ischemia in mice. Stroke, 34, 1304-1310. (Pubitemid 36547533)
34. Kim DW, Eum WS, Jang SH, Kim SY, Choi HS, Choi SH, An JJ, Lee SH, Lee KS, Han K, Kang TC, Won MH, Kang JH, Kwon OS, Cho SW, Kim TY, Park J, Choi SY. (2005). Transduced Tat-SOD fusion protein protects against ischemic brain injury. Mol Cells, 19, 88-96.
35. Kim JE, Liu BP, Park JH, Strittmatter SM. (2004). Nogo-66 receptor prevents raphespinal and rubrospinal axon regeneration and limits functional recovery from spinal cord injury. Neuron, 44, 439-451.
36. Lansberg MG, Schwartz NE. (2009). Tissue plasminogen activator does not benefit most eligible patients with stroke. Arch Neurol, 66, 540-541; author reply 541.
37. Laurén J, Airaksinen MS, Saarma M, Timmusk T. (2003). Two novel mammalian Nogo receptor homologs differentially expressed in the central and peripheral nervous systems. Mol Cell Neurosci, 24, 581-594. (Pubitemid 37506003)
38. Laurén J, Hu F, Chin J, Liao J, Airaksinen MS, Strittmatter SM. (2007). Characterization of myelin ligand complexes with neuronal Nogo-66 receptor family members. J Biol Chem, 282, 5715-5725. (Pubitemid 47093783)
39. Lee JK, Kim JE, Sivula M, Strittmatter SM. (2004). Nogo receptor antagonism promotes stroke recovery by enhancing axonal plasticity. J Neurosci, 24, 6209-6217. (Pubitemid 38891112)
40. Legg LA, Drummond AE, Langhorne P. (2006). Occupational therapy for patients with problems in activities of daily living after stroke. Cochrane Database Syst Rev, CD003585. (Pubitemid 46841272)
41. Li S, Liu BP, Budel S, Li M, Ji B, Walus L, Li W, Jirik A, Rabacchi S, Choi E, Worley D, Sah DW, Pepinsky B, Lee D, Relton J, Strittmatter SM. (2004). Blockade of Nogo-66, myelin-associated glycoprotein, and oligodendrocyte myelin glycoprotein by soluble Nogo-66 receptor promotes axonal sprouting and recovery after spinal injury. J Neurosci, 24, 10511-10520. (Pubitemid 39552636)
42. Li S, Strittmatter SM. (2003). Delayed systemic Nogo-66 receptor antagonist promotes recovery from spinal cord injury. J Neurosci, 23, 4219-4227. (Pubitemid 36958442)
43. Liu BP, Fournier A, GrandPré T, Strittmatter SM. (2002). Myelinassociated glycoprotein as a functional ligand for the Nogo-66 receptor. Science, 297, 1190-1193. (Pubitemid 36193355)
44. McGee AW, Strittmatter SM. (2003). The Nogo-66 receptor: Focusing myelin inhibition of axon regeneration. Trends Neurosci, 26, 193-198.
45. Mehta NR, Lopez PH, Vyas AA, and Schnaar RL. (2007). Gangliosides and Nogo receptors independently mediate myelin-associated glycoprotein inhibition of neurite outgrowth in different nerve cells. J Biol Chem, 282,27875-27886.
46. Mi S, Lee X, Shao Z, Thill G, Ji B, Relton J, Levesque M, Allaire N, Perrin S, Sands B, Crowell T, Cate RL, McCoy JM, Pepinsky RB. (2004). LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex. Nat Neurosci, 7, 221-228. (Pubitemid 38280445)
47. Mingorance A, Solé M, Munetón V, Martínez A, Nieto-Sampedro M, Soriano E, del Río JA. (2006). Regeneration of lesioned entorhinohippocampal axons in vitro by combined degradation of inhibitory proteoglycans and blockade of Nogo-66/NgR signaling. FASEB J, 20, 491-493. (Pubitemid 46671226)
48. Misra A, Ganesh S, Shahiwala A, Shah SP. (2003). Drug delivery to the central nervous system: A review. J Pharm Pharm Sci, 6, 252-273. (Pubitemid 37207232)
49. Ogasawara K, Yamadate K, Kobayashi M, Endo H, Fukuda T, Yoshida K, Terasaki K, Inoue T, Ogawa A. (2005). Effects of the free radical scavenger, edaravone, on the development of postoperative cognitive impairment in patients undergoing carotid endarterectomy. Surg Neurol, 64, 309-313; discussion 313. (Pubitemid 41337891)
50. Pardridge WM. (2005). The blood-brain barrier: Bottleneck in brain drug development. NeuroRx, 2, 3-14. (Pubitemid 40128022)
51. Park JB, Yiu G, Kaneko S, Wang J, Chang J, He XL, Garcia KC, He Z. (2005). A TNF receptor family member, TROY, is a coreceptor with Nogo receptor in mediating the inhibitory activity of myelin inhibitors. Neuron, 45, 345-351. (Pubitemid 40188202)
52. Pignot V, Hein AE, Barske C, Wiessner C, Walmsley AR, Kaupmann K, Mayeur H, Sommer B, Mir AK, Frentzel S. (2003). Characterization of two novel proteins, NgRH1 and NgRH2, structurally and biochemically homologous to the Nogo-66 receptor. J Neurochem, 85, 717-728. (Pubitemid 36531935)
53. Prinsloo E, Oosthuizen V, Muramoto K, Naude RJ. (2006). In vitro refolding of recombinant human free secretory component using equilibrium gradient dialysis. Protein Expr Purif, 47, 179-185. (Pubitemid 44419330)
54. Salter K, Hellings C, Foley N, Teasell R. (2008). The experience of living with stroke: A qualitative meta-synthesis. J Rehabil Med, 40, 595-602.
55. Saver JL. (2006). Time is brain-quantified. Stroke, 37, 263-266.
56. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. (1999). In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science, 285, 1569-1572. (Pubitemid 29420581)
57. Shao Z, Browning JL, Lee X, Scott ML, Shulga-Morskaya S, Allaire N, Thill G, Levesque M, Sah D, McCoy JM, Murray B, Jung V, Pepinsky RB, Mi S. (2005). TAJ/TROY, an orphan TNF receptor family member, binds Nogo-66 receptor 1 and regulates axonal regeneration. Neuron, 45, 353-359. (Pubitemid 40188203)
58. Steward O, Sharp K, Yee KM, Hofstadter M. (2008). A re-assessment of the effects of a Nogo-66 receptor antagonist on regenerative growth of axons and locomotor recovery after spinal cord injury in mice. Exp Neurol, 209, 446-468.
59. Szeder V, Torbey MT. (2008). Prevention and treatment of perioperative stroke. Neurologist, 14, 30-36.
60. Teng FY, Tang BL. (2005). Why do Nogo/Nogo-66 receptor gene knockouts result in inferior regeneration compared to treatment with neutralizing agents? J Neurochem, 94, 865-874.
61. Toyoda K, Fujii K, Kamouchi M, Nakane H, Arihiro S, Okada Y, Ibayashi S, Iida M. (2004). Free radical scavenger, edaravone, in stroke with internal carotid artery occlusion. J Neurol Sci, 221, 11-17. (Pubitemid 38721285)
62. Uno M, Kitazato KT, Suzue A, Matsuzaki K, Harada M, Itabe H, Nagahiro S. (2005). Inhibition of brain damage by edaravone, a free radical scavenger, can be monitored by plasma biomarkers that detect oxidative and astrocyte damage in patients with acute cerebral infarction. Free Radic Biol Med, 39, 1109-1116. (Pubitemid 41356601)
63. van de Waterbeemd H, Camenisch G, Folkers G, Chretien JR, Raevsky OA. (1998). Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J Drug Target, 6, 151-165. (Pubitemid 29033982)
64. Venkatesh K, Chivatakarn O, Sheu SS, Giger RJ. (2007). Molecular dissection of the myelin-associated glycoprotein receptor complex reveals cell type-specific mechanisms for neurite outgrowth inhibition. J Cell Biol, 177, 393-399. (Pubitemid 46718269)
65. Wang F, Liang Z, Hou Q, Xing S, Ling L, He M, Pei Z, Zeng J. (2007). Nogo-A is involved in secondary axonal degeneration of thalamus in hypertensive rats with focal cortical infarction. Neurosci Lett, 417, 255-260. (Pubitemid 46589790)
66. Wang KC, Kim JA, Sivasankaran R, Segal R, He Z. (2002a). P75 interacts with the Nogo receptor as a co-receptor for Nogo, MAG and OMgp. Nature, 420, 74-78. (Pubitemid 35291442)
67. Wang Q, Gou X, Jin W, Xiong L, Hou L, Chen S, Zhang H, Zhu X, Xu L. (2009). TAT-mediated protein transduction of Nogo extracellular peptide 1-40 and its biological activity. Cell Mol Neurobiol, 29, 97-108.
68. Wang Q, Gou X, Xiong L, Jin W, Chen S, Hou L, Xu L. (2008). Transactivator of transcription-mediated delivery of NEP1-40 protein into brain has a neuroprotective effect against focal cerebral ischemic injury via inhibition of neuronal apoptosis. Anesthesiology, 108, 1071-1080.
69. Wang X, Baughman KW, Basso DM, Strittmatter SM. (2006). Delayed Nogo receptor therapy improves recovery from spinal cord contusion. Ann Neurol, 60, 540-549. (Pubitemid 44871796)
70. Wang X, Chun SJ, Treloar H, Vartanian T, Greer CA, Strittmatter SM. (2002b). Localization of Nogo-A and Nogo-66 receptor proteins at sites of axon-myelin and synaptic contact. J Neurosci, 22, 5505-5515. (Pubitemid 35386472)
71. West C, Bowen A, Hesketh A, Vail A. (2008). Interventions for motor apraxia following stroke. Cochrane Database Syst Rev, CD004132. (Pubitemid 351807577)
72. Wong ST, Henley JR, Kanning KC, Huang KH, Bothwell M, Poo MM. (2002). A p75(NTR) and Nogo receptor complex mediates repulsive signaling by myelin-associated glycoprotein. Nat Neurosci, 5, 1302-1308. (Pubitemid 35417765)
73. Yepes M, Roussel BD, Ali C, Vivien D. (2009). Tissue-type plasminogen activator in the ischemic brain: More than a thrombolytic. Trends Neurosci, 32, 48-55.
74. Yiu G, He Z. (2006). Glial inhibition of CNS axon regeneration. Nat Rev Neurosci, 7, 617-627. (Pubitemid 44106744)
75. Zheng B, Atwal J, Ho C, Case L, He XL, Garcia KC, Steward O, Tessier-Lavigne M. (2005). Genetic deletion of the Nogo receptor does not reduce neurite inhibition in vitro or promote corticospinal tract regeneration in vivo. Proc Natl Acad Sci USA, 102, 1205-1210. (Pubitemid 40170750)